Valuation: Gencurix Inc.

Market Cap 30.03B 22.14M 19.54M 18.49M 16.77M 31.43M 2.12B 31.74M 222M 85.48M 1.08B 83.14M 81.33M 3.49B P/E 2022
-1.86x
P/E 2023 -3.82x
Enterprise Value 35.66B 26.3M 23.21M 21.96M 19.91M 37.33M 2.52B 37.7M 263M 102M 1.29B 98.74M 96.59M 4.15B EV / Sales 2022
26.8x
EV / Sales 2023 34.6x
Free-Float
55.38%
Yield 2022 *
-
Yield 2023 -
1 day+0.88%
Current month-1.16%
1 month-0.41%
3 months-10.64%
6 months-27.11%
Current year+26.18%
1 month 1,813
Extreme 1813
2,370
Current year 1,321
Extreme 1321
7,320
1 year 1,321
Extreme 1321
7,320
3 years 1,131
Extreme 1131
8,500
5 years 1,131
Extreme 1131
19,450
10 years 1,131
Extreme 1131
32,300
Manager TitleAgeSince
Chief Executive Officer 53 -
Chief Tech/Sci/R&D Officer 64 01/01/2015
Corporate Officer/Principal 61 31/03/2023
Director TitleAgeSince
Director/Board Member 53 -
Director/Board Member 61 31/03/2023
Director/Board Member 43 13/09/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%0.00%+18.61%-69.08% 33.8M
+0.23%+0.32%+186.71%+499.63% 23.85B
+1.74%+11.57%+694.00%+118.28% 11.73B
-0.19%+4.94%-30.93%-13.85% 10.5B
-0.63%+0.25%+5.17% - 8.92B
-0.23%-0.49%+96.58%+43.22% 6.5B
-0.08%+0.20%-26.09%-21.96% 5.8B
-0.15%+0.33%+3.79%-9.16% 4.4B
+1.96%-6.23%+56.93%+61.68% 3.77B
-1.52%-3.89%-14.26%-26.50% 2.86B
Average +0.20%+1.75%+99.05%+64.69% 7.84B
Weighted average by Cap. +0.24%+2.57%+165.66%+193.31%

Financials

2022 2023
Net sales 2.56B 1.89M 1.67M 1.58M 1.43M 2.68M 181M 2.71M 18.9M 7.29M 92.47M 7.09M 6.93M 298M 2.6B 1.92M 1.69M 1.6M 1.45M 2.72M 184M 2.75M 19.2M 7.4M 93.94M 7.2M 7.04M 302M
Net income -24.6B -18.14M -16M -15.14M -13.73M -25.75M -1.74B -26M -182M -70.01M -889M -68.1M -66.62M -2.86B -19.26B -14.2M -12.53M -11.86M -10.75M -20.16M -1.36B -20.36M -142M -54.82M -696M -53.32M -52.16M -2.24B
Net Debt 22.55B 16.63M 14.67M 13.88M 12.59M 23.6M 1.6B 23.84M 167M 64.18M 815M 62.43M 61.07M 2.62B 5.63B 4.15M 3.67M 3.47M 3.15M 5.9M 399M 5.95M 41.6M 16.03M 204M 15.6M 15.26M 655M
Logo Gencurix Inc.
Gencurix Inc. is a Korea-based company mainly engaged in the sale of medical equipments. In addition, the Company is involved in the manufacturing and sale of breast cancer test (BCT) kits, Korean genetic polymorphism diagnostic kits, lung cancer and colorectal cancer diagnostic kits. The BCT kits are used for analyzing the expression level of the cancer-related gene. The products are sold under the name of GenesWell.
Employees
-
  1. Stock Market
  2. Stocks
  3. A229000 Stock